Glenmark JV IGI unveils ISB 2301 to target solid tumors

Glenmark Pharmaceuticals ' joint venture, Ichnos Glenmark Innovation (IGI), has introduced ISB 2301, a first-in-class, multispecific immune cells activator designed for the potential treatment of multiple solid tumor indications. The announcement marks a significant advancement in the venture's oncology pipeline, leveraging its proprietary BEAT® technology platform to address the biological complexity of solid tumors.

ISB 2301: A Multispecific Immune Cells Activator

ISB 2301 is a next-generation multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death. It engages both T cells and natural killer (NK) cells to ignite the immune system, offering a multi-mechanistic approach to cancer treatment. The candidate is classified as a first-in-class molecule, designed to induce potent antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and a sustained type 1 immune response.

Parameter	Details
Candidate Name	ISB 2301
Classification	First-in-Class Multispecific Immune Cells Activator
Target Indication	Multiple Solid Tumors
Mechanism	Targets 3 Tumor-Associated Antigens; Activates T and NK Cells
Introduced By	IGI (Joint Venture of Glenmark Pharmaceuticals)

Strategic Development and Clinical Plans

The development of ISB 2301 was enabled by IGI's clinically validated BEAT® platform, which allows for manufacturing with a standard multispecific antibody process. Preclinical data indicates that ISB 2301 demonstrates excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates. Building on the platform's success, IGI intends to submit an Investigational New Drug (IND) application for ISB 2301 by the end of this year, with clinical studies scheduled to begin in 2027.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.12%	+5.40%	+5.76%	+29.24%	+65.38%	+287.14%

Glenmark Pharmaceuticals has scheduled a meeting of its board of directors on Friday, May 29, 2026. The meeting has been convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the standalone and consolidated audited financial results of the company for the quarter and year ended March 31, 2026. Additionally, the board will deliberate on and recommend a dividend on equity shares for the fiscal year ended March 31, 2026, if any.

Trading Window Closure

In accordance with the "Code of Conduct for Prevention of Insider Trading" and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has informed its directors and other designated persons about the closure of the trading window. This closure is effective from March 31, 2026, to May 31, 2026, inclusive, to facilitate the approval of the audited financial results.

The meeting will be held to review the company's financial performance for the full fiscal year and the final quarter. Shareholders and investors await the board's decision regarding the potential dividend declaration for the year ended March 31, 2026.